Enamine Joins Open-Science Drug Discovery Initiative

Collaboration Targets Novel Treatments for Rare Neuromuscular Disease

Enamine has announced its participation in an open-science collaboration with Agora Open Science Trust and Variational AI to accelerate the discovery of novel PRMT6 inhibitors. The initiative focuses on developing potential treatments for Spinal and Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder that currently has no approved therapies capable of slowing or stopping disease progression.

AI-Powered Drug Discovery Framework

The collaboration brings together expertise in medicinal chemistry, artificial intelligence, machine learning, structural biology and preclinical research. Variational AI will utilize its Enki™ generative AI platform to design new PRMT6 inhibitor candidates, while participating organizations contribute biological testing, validation and development capabilities within a transparent design-make-test-analyze (DMTA) workflow.

Accelerating Discovery Through Synthetic Chemistry

A key component of the project is the integration of Enamine's REAL Space and xREAL chemical space, among the world's largest synthetically validated chemical libraries. By ensuring that AI-generated molecules are synthetically feasible from the beginning, the collaboration aims to shorten development cycles, improve efficiency and accelerate the identification of promising drug candidates.

Advancing Open Science in Drug Development

In line with Agora Open Science Trust's principles, all project data, including molecular structures, assay results and research findings, will be made publicly available. The initiative demonstrates how open-science collaboration, AI-driven molecular design and advanced chemistry capabilities can work together to accelerate therapeutic innovation for underserved diseases.

Key Features

• Open-science collaboration for PRMT6 inhibitor discovery

• Focused on treating Spinal and Bulbar Muscular Atrophy (SBMA)

• AI-driven molecular design using Enki™ platform

• Integration of Enamine REAL Space and xREAL chemical libraries

• Transparent design-make-test-analyze (DMTA) workflow

• Public sharing of research data and findings

• Rapid synthesis and validation of novel compounds

• Collaboration between academia, biotech and research organizations

Applications

• Rare disease drug discovery

• Neuromuscular disease research

• AI-assisted medicinal chemistry

• Small-molecule inhibitor development

• Open-science pharmaceutical research

• Preclinical drug development programs

• Computational drug design platforms

• Structure-activity relationship (SAR) studies

Accelerating AI-Driven Therapeutic Innovation

As the pharmaceutical industry increasingly adopts artificial intelligence and collaborative research models, open-science initiatives are emerging as powerful tools for accelerating drug discovery. The partnership between Enamine, Agora Open Science Trust and Variational AI highlights how combining generative AI, advanced chemistry and transparent research practices can help advance potential therapies for rare diseases while expanding scientific knowledge across the broader research community.